Most Read Articles
Elvira Manzano, 02 Oct 2018
Triple therapy with budesonide, glycopyrrolate, and formoterol in one metered dose inhaler (BGF MDI) appears effective and is well-tolerated in patients with symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD) irrespective of exacerbation history, the multicentre, phase III KRONOS* trial has shown.
Dr. Fanny Wai-San Ko, Dr. Wing-Ho Yip, 15 Aug 2018
Although a majority of patients can achieve good asthma control with the use of inhaled corticosteroid (ICS) and bronchodilators, some patients’ asthma remain uncontrolled despite the use of these medications.
Stephen Padilla, 14 Jan 2019
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.
20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.

High-dose rifampin may help shorten tuberculosis treatment

08 Jul 2018
There were approximately 36 cases of TB per 100,000 population in Singapore last year

Higher doses of rifampin result in more rapid sputum sterilization and similar toxicity, a study has shown. These findings support the investigation of increased rifampin doses to shorten tuberculosis treatment.

To determine whether increased rifampin doses could shorten standard therapy for tuberculosis without increased toxicity, the investigators conducted a blinded, randomized, controlled phase II clinical trial involving 180 adults with new smear-positive pulmonary tuberculosis, susceptible to isoniazid and rifampin. Participants were randomized 1:1:1 to 10, 15 and 20 mg/kg/day of rifampin during the intensive phase.

The primary efficacy and safety endpoints were as follows: change in elimination rate of M. tuberculosis log10 colony forming units and frequency of grade 2 rifampin related adverse events (AEs). Efficacy by treatment arm and by primary (AUC/MIC) and secondary (AUC) pharmacokinetic exposure was also reported.

Differences of –0.011 (95 percent CI, –0.025 to 0.002; p=0.230) and –0.022 (–0.046 to –0.002; p=0.022) log10 colony forming units/mL/day were recorded in the modified intention-to-treat and per-protocol analyses, respectively, for every 5 mg/kg/day increase in rifampin dose. In the per-protocol group, elimination rate significantly increased with rifampin AUC0-6 (p=0.011) but not with AUC0-6/MIC99.9 (p=0.053).

Occurrence of grade 2 rifampin-related AEs showed similar frequency across the three treatment arms: 26 (43.3 percent), 31 (51.7 percent) and 23 (38.3 percent) participants in the 10, 15 and 20 mg/kg/day rifampin dose groups, respectively, had at least one AE (p=0.7092) up to 4 weeks after the intensive phase. In addition, 11 (6.1 percent) participants had treatment failure or disease recurrence.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 02 Oct 2018
Triple therapy with budesonide, glycopyrrolate, and formoterol in one metered dose inhaler (BGF MDI) appears effective and is well-tolerated in patients with symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD) irrespective of exacerbation history, the multicentre, phase III KRONOS* trial has shown.
Dr. Fanny Wai-San Ko, Dr. Wing-Ho Yip, 15 Aug 2018
Although a majority of patients can achieve good asthma control with the use of inhaled corticosteroid (ICS) and bronchodilators, some patients’ asthma remain uncontrolled despite the use of these medications.
Stephen Padilla, 14 Jan 2019
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.
20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.